CAR-T For Relapsed/Refractory AML: From Discovery To First-In-Human Active Phase 1 Evaluation

CAR T-cell therapy for acute myeloid leukemia (AML) faces a critical challenge: many promising targets, including CD33 and CD123, are also found on healthy hematopoietic stem and progenitor cells. Targeting these antigens can cause prolonged myelosuppression and bone marrow aplasia. Dr. Marco Davila examines a different approach centered on CD83, an antigen highly expressed on AML blasts but distinctly regulated in healthy tissues. Anti-CD83 CAR T cells may selectively suppress leukemia while preserving essential progenitor cells. Explore how CD83 could help establish new safety and efficacy benchmarks for myeloid cell therapy.